A multivariate analysis of patients with brain tumors treated with ATN-RNA

Acta Pol Pharm. 2008 Nov-Dec;65(6):677-84.


Glioblastoma multiforme (GBM) is the most common form of malignant glioma, characterized by genetic instability, intratumoral histopathological variability, and unpredictable clinical behavior. Malignant gliomas express preferentially a number of surface markers that may be exploited as therapeutic targets, such as tenascin-C, an extracellular matrix glycoprotein contributes to tumor cell adhesion, invasion, migration and proliferation. Disappointing results in the treatment of gliomas with surgery, radiation and chemotherapy have fuelled a search for new treatment modalities. Here we present the data for 46 patients suffering from brain tumor. They were resected and treated with dsRNA (ATN-RNA) complementary to the sequence of tenascin-C mRNA. MRI and CT follow up studies showed growth tumor delay or lack of its recurrence symptoms, due to inhibition of TN-C synthesis. A significant improvement in overall survival (OS) was observed without loosing of the quality of life (QOL) of patients. This novel therapy based on RNA interference shows a big therapeutical potential. To our knowledge intervention with RNAi (iRNAi) is the first protocol of application of RNAi in human disease treatment.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Base Sequence
  • Brain Neoplasms / physiopathology
  • Brain Neoplasms / therapy*
  • Female
  • Follow-Up Studies
  • Glioblastoma / physiopathology
  • Glioblastoma / therapy
  • Glioma / physiopathology
  • Glioma / therapy*
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Neoplasm Recurrence, Local
  • Quality of Life
  • RNA Interference
  • RNA, Double-Stranded / therapeutic use*
  • RNA, Messenger / metabolism
  • Survival Rate
  • Tenascin / genetics
  • Tenascin / metabolism*
  • Tomography, X-Ray Computed
  • Young Adult


  • RNA, Double-Stranded
  • RNA, Messenger
  • Tenascin